Alan Schlussel
Corneal and Contact Management · West Orange, NJNPI 1538161740
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (39.7%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by Lumenis BE Inc at 54.0% of the total. Reporting peaked in 2022 at $3,671 and has fallen 93.1% since, to $254 in 2025. Among corneal and contact management clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 64 payments — averaging $126.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lumenis BE Inc$4K
- Eyevance Pharmaceuticals LLC$1K
- Shire North American Group Inc$819
- Johnson & Johnson Surgical Vision, Inc.$440
- Alcon$357
- Bausch & Lomb Americas Inc.$290
- plus $780 from 8 others
What the payments were for
- Consulting fees$2,13026%
- Speaking & faculty fees$3,22240%
- Travel & lodging$781%
- Food & beverage$2,66733%
- Education$180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lumenis BE Inc | 2 | $4,383 |
| Eyevance Pharmaceuticals LLC | 4 | $1,045 |
| Shire North American Group Inc | 5 | $819 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $440 |
| Alcon | 12 | $357 |
| Bausch & Lomb Americas Inc. | 11 | $290 |
| Sight Sciences, Inc. | 2 | $155 |
| Johnson & Johnson Vision Care, Inc. | 6 | $150 |
| Ocular Therapeutix, Inc. | 1 | $134 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 6 | $101 |
| Tarsus Pharmaceuticals, Inc. | 4 | $86 |
| Sun Pharmaceutical Industries Inc. | 5 | $77 |
| Oyster Point Pharma, Inc. | 3 | $50 |
| AbbVie | 2 | $28 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- optilight$3,222
- M22$1,161
- Flarex$1,000
- XIIDRA$690
- One Series Ultra IOL Delivery System$440
- TearCare SmartLid$137
- TEARCARE(TM) (2.2) SYSTEM KIT$137
- DEXTENZA$134
- Precision 1$133
- INFUSE$130
How this compares
$8,114 in reported general payments places this provider in the 90th percentile of 45 corneal and contact management providers in New Jersey.
See all corneal and contact management providers in New Jersey →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 27 | $25,016 |
| MieboPerfluorohexyloctane/Pf | 17 | $17,617 |
| CequaCyclosporine | 11 | $12,333 |
| Cyclosporine | 22 | $7,448 |
| Loteprednol Etabonate | 18 | $3,931 |
| Cevimeline Hcl | 12 | $516 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 13 | $489 |
| Latanoprost | 18 | $167 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $290 | $42,63344 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $77 | $12,33311 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $101 | $3,93118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 45 corneal and contact management providers in New Jersey.
Other corneal and contact management in West Orange
- Bradford RippsLake Hopatcong$94K
- Vittorio MenaFairview$53K
- Kenneth DanielsLambertville$14K
- Thomas ConroyBloomfield$9K
- Danica YangCranford$7K
- Daniel IsaacCherry Hill$5K
- Amy SteinParamus$4K
- Paul DifioreMount Laurel$3K
- Jeffrey CaseFreehold$3K
- Saras RustagiWest New York$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.